Round Table: Discussion of Regulatory Considerations for Genetically Engineered iPSC-derived Cell Therapies

Time: 1:30 pm
day: Day 2 Tracks 2 PM Clarice


  • CMC characterization and reagent quality
  • Balancing the regulatory approach for platform product manufacture and uniqueness of engineered cellular therapy
  • Regulatory challenges to clinical entry for genetically engineered iPSC-derived cell therapies